He did not specify the US financial commitment, describing it only as “significant”.
Lenacapavir, marketed under the brand name Yeztugo, is manufactured by California-based Gilead Sciences, which has said it will provide the drug at no profit as part of the partnership.
The initiative aims to reach at least two million people by 2028. The participating countries are yet to be named.
Many experts are hopeful that the antiretroviral drug, already approved in a number of countries to help treat adults with multidrug-resistant HIV, could dramatically speed up the fight against the virus.
Lewin said the US role in the partnership would be limited to purchasing and supplying lenacapavir to local governments, who would then be responsible to distribute the medication themselves.
“There are no NGOs involved in this. There are none of those sort of beltway bandits here,” Lewin said, employing a derogatory term for US federal government contractors.
Trump, with the help of billionaire donor Elon Musk, has taken a sledgehammer to foreign aid and effectively dismantled USAid - the world’s largest humanitarian aid agency - as part of wider cost-cutting measures.
He has also pulled back on Pepfar’s roughly US$6 billion ($10.2b) annual funding, limiting its work to pregnant and breastfeeding women.
UNAids in April warned that a permanent discontinuation of Pepfar would lead to more than six million new infections and an additional 4.2 million Aids-related deaths in the next four years.
-Agence France-Presse